Dynavax Technologies Retained Earnings (Accumulated Deficit) 2010-2024 | DVAX

Dynavax Technologies retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Dynavax Technologies Retained Earnings (Accumulated Deficit) 2010-2024 | DVAX

Dynavax Technologies retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$158.3B
Bristol Myers Squibb (BMY)$119.4B
Vertex Pharmaceuticals (VRTX)$116.1B
Gilead Sciences (GILD)$112.4B
CSL (CSLLY)$87.2B
Regeneron Pharmaceuticals (REGN)$81.1B
GSK (GSK)$70.4B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$31.6B
BioNTech SE (BNTX)$27.1B
Biogen (BIIB)$23B
Illumina (ILMN)$22.2B
BeiGene (BGNE)$18.6B
Moderna (MRNA)$15.8B
Incyte (INCY)$13.8B
Genmab (GMAB)$13.7B
Insmed (INSM)$13.1B
BioMarin Pharmaceutical (BMRN)$12.2B
Bio-Techne Corp (TECH)$11.3B
Vaxcyte (PCVX)$11B
Sarepta Therapeutics (SRPT)$10.9B
Exelixis (EXEL)$10.2B
Exact Sciences (EXAS)$9.8B
QIAGEN (QGEN)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$9.3B
Intra-Cellular Therapies (ITCI)$9.1B
Repligen (RGEN)$8B
Ascendis Pharma (ASND)$7.9B